In this episode of the Pharmaceutical Executive podcast, Charlotte Owens, MD, FACOG, Head of Medical Affairs and Outcomes Research at Organon discusses:

• The broader societal implications of these maternal health issues highlighted in The Commonwealth Fund study
• The most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make
• Specific efforts Organon is undertaking to invest in research, education, and its pipeline to focus on critical areas of need in maternal health
• How her in-practice experience as an OB-GYN are informing Organon's strategic approach to addressing maternal health challenges
• and more!

Michael Abrams, Managing Partner at Numerof & Associates discusses pharmacy deserts and the main factors that are contributing to the closures of both large and independent pharmacies, what alternative solutions can help ensure continued access to medications for all Americans (particularly those in underserved communities), some potential long term consequences if these pharmacy closures continue, and so much more

Dr. Julien Boisdron, Global Head of OneMedical / Chief Medical Officer Roche Diabetes Care, discusses the current standard for diabetes care, the importance of patient advocacy and mental health, what the future of this space holds, and much more. 

Krystle Buntemeyer, president of SCORR Marketing, and Bharat Mehta, co-founder of PharmaCompass, discuss a new, free online tool called Pipeline Prospector, which they recently launched in collaboration. The tool aims to provide pharma executives with industry data, including deal and pipeline information, to help them make more informed decisions.

Dr. Gregg Sylvester, chief medical officer of Seqirus, discusses the importance of vaccinating against the seasonal flu amid the COVID pandemic, and how the two viruses should be considered in light of each other.

Panna Sharma, CEO of Lantern Pharma, discusses garage biotech, what he’s learned from the culture, and how it might help transform certain areas of pharma, including innovation and pricing.

Sanjeev Luther, president and CEO of Rafael Pharmaceuticals, discusses how he managed to turn around a company on the brink of bankruptcy and advance clinical trials for its lead cancer drug through COVID-19.

Dr. Neil Hayward, CEO and founder of eXlthera, is here to discuss his company, which is developing Factor XI inhibitor antithrombotics that are attacking blood clots from a new angle and are giving patients new hope.

George Baxter, CEO of Edinburgh Innovations, is here to discuss the company's commercialization model, and how his group is bringing innovation to market in Scotland.

Jack Khattar, president and CEO of Supernus Pharmaceuticals, talks about his experience bringing ADHD drugs to market in a challenging environment.

Eric Turbiville, author of the recently published book “The Perfect Leadership Triad: How Top Executives Maximize Productivity through People, Coaching, and Performance," a 25-year pharma veteran, credentialed executive coach, and director of mentoring for the Southwest region of the Healthcare Businesswomen’s Association says there are three leadership principles can help executives through tumultuous times, and is here to discuss how they can impact success.

Kurt Orlofski, CEO of Pharmaceutical Associates Inc., discusses what the pharmaceutical supply chain might look like post COVID-19, and how companies can prepare for that.

Jim and Cindy DiBiasi, co-founders of 3D Communications, talk about how to prepare for virtual high-level meetings, such as important regulatory presentations and keynote addresses, in the wake of COVID-19.

Edward Triebell, Commercial Executive Director for MRN Technologies, discusses the biggest digital trends in clinical research right now, how COVID-19 impacted the use of digital within sponsors and CROs, what the future of DCT services looks like, and much more.

Tim Walbert, CEO of Horizon Therapeutics, shares his unique perspective on managing the Chicago location of the company through COVID-19, in light of the fact that he himself is immunocompromised.

Janice Kranz, co-founder of Eikonizo Therapeutics, bring us up to date on how targeting tau to fight Alzheimer’s and other neurodegenerative diseases is making waves in the CNS space.

Dr. Jonathan Gertler, CEO of Back Bay Life Science Advisors, and Dr. Stephan Gauldie, Managing Director of Back Bay, talk about the new guidelines set forth by FDA in regard to gene therapy, and what those new parameters mean for pharma and biotech.

Pratap Khedkar, managing principal of ZS Associates, talks about pharma’s scenario planning amid COVID-19 as it looks to settle into a new normal.

Lew Bender, founder of Intensity Therapeutics and the inventor of Intensity’s DfuseRx platform technology, discusses the technology that allows the company’s therapeutic products to be injected directly into solid tumors, this innovative process successfully kills tumors and activates an immune response to shut down cancer cells throughout the body.

Kathrin Jansen, Senior Vice President and Head of Vaccine Research and Development at Pfizer, talks about the challenges of creating a new maternal vaccine for respiratory syncytial virus, also known as RSV, currently being administered to pregnant women in trials, in the hopes of protecting their infants.

Chris Paquette, DeepIntent co-founder and CEO, talks about the evolution of digital marketing in pharma, specifically, how to approach data and technology usage in a privacy-first world.

Barbara Ryan, founder of Barbara Ryan Advisors, a member of PharmExec’s editorial advisory board, and the founder of Fabulous Pharma Females discusses the strong community she’s built providing women the opportunity to connect with each other and reinforce their shared commitment to one another.

Yuval Cohen, CEO of Corbus Pharmaceuticals, talks about cannabinoids, the differences between natural and synthetic products, and how biotechs and pharma are using them to treat disease today.

Dr. Eric von Hofe, Chief Scientific Officer at NuGenerex Immuno-Oncology talks about the recent outbreak of Wuhan coronavirus around the world and how biotechs and pharma are jumping in to help find a solution.

David Klein, co founder and CEO of Click Therapeutics, discusses the new FDA SaMD guidance, the clear differences between companion apps and SaMD, and gives insight into what to expect from this combination in the future.

Mike Strazzella, head of federal government relations for Buchanan Ingersoll & Rooney, talks about pricing issues in the pharmaceutical industry, the challenges he encounters, and what he believes needs to change in the industry going forward.

Pharm Exec speaks with Nigel Breakwell and Ben Randal, co-founders of Dot I/O Health. Nigel and Ben talk about how they’re using data science in the health and life sciences industries to help clients navigate emerging markets.

Pharm Exec editors discuss the themes chosen for the January issue focusing on industry trends for the coming year.

Heather Monte, Director of Operations for DirectRx, talks about the specialty pharma’s new Patient Scorecard, which aims to identify and improve adherence by reporting patients’ prescription patterns to doctors.

Julia Owens, co-founder and CEO of Millendo Therapeutics talks about how to keep a company on the path to success, even when there are bumps in the road. She discusses the value of focusing on strengths and how that is currently working for Millendo in the endocrine space.

William Lewis, chairman and CEO of Insmed talks about the approval of the company’s drug Arikayce through the FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs, some ideas that he spoke about on the recent NORD panel about innovative and ethical partnerships, and Insmed’s pipeline and progress.

Pharm Exec editors discuss the articles they focused on for the November Annual Pipeline Report.

Sven Klingemann, research director at Reputation Institute talks about pharma’s negative public perception and what the industry can do to improve it.

Pharm Exec editors interview Mark Glickman, Chief Commercial Officer of Esperion Therapeutics. Glickman discusses the overall cholesterol-lowering space and how it’s planning to add a new therapeutic option for patients, what it means to establish a new therapy in a statin-dominated market, market research approaches, and more.

Jeannine Lynch, senior director at BioMarin Pharmaceuticals, oversees patient access services and talks with editors about the patient journey in regard to receiving therapies, how to engage with patients more effectively, and where she sees the pharma industry in terms of patient engagement and patient centricity.

In this exclusive Pharm Exec Podcast episode with Paul Biondi, executive partner at Flagship Pioneering (the venture creation firm behind Moderna and many other life science firms) and president of Pioneering Medicines, Meg Rivers, managing editor, asks Biondi about 1) the process of founding a company; 2) what factors they consider when deciding whether to partner with a pharmaceutical company (like your partnership with Novo Nordisk) or a foundation (like your partnership with the Cystic Fibrosis Foundation)—along with what makes one organization stand out from another; 3) where science is booming in pharma right now; 4) deciding whether to found a company looking to launch innovations in an existing space vs. pursue innovations in an untapped space; and 5) signs that a company will achieve commercial success from early on.

Janssen’s company group chairman of Europe, Middle East, and Africa operations, Kris Sterkens speaks with Pharm Exec editors. Kris talks about his finance background, global pricing issues, and challenges and opportunities for EMEA biopharma breaking into the US market.

Apellis’ CEO and co-founder, Dr. Cedric Francois talks with editors about his unusual pharma journey, which has included research, clinical work, and the launch of two startups. Today, he’s here to share what he’s learned along the way and how he’s using that experience to improve lives.

Christine Sakdalan, Head of Franchise Strategy and Customer Solutions at Janssen Pharmaceutical talks with Pharm Exec editors about how patient-centricity fuels innovation, the difference between patient and customer centricity, and educational programs that need to be implemented for patients, providers, and payers.

Pharm Exec editors sit down with Mark Velleca, CEO of G1 Therapeutics. In this episode, Mark talks about how he differentiates himself in the oncology field, why he considers G1 Therapeutics an "old school company," and about the North Carolina biotech landscape.

Pharm Exec editors share insights into what they've been working on this summer for the June, July, and August issues; plus a sneak peek into what's coming in September!

Robert Finkel, the CEO of The FreshBlood Group talks with Pharm Exec editors about the positives and negatives of pharma’s marketing needs, the details and evolution around founding The FreshBlood Group, and how emerging pharma and biotech companies can budget in successful marketing.

Cameron Turtle, Chief Business Officer of Eidos Therapeutics, Robin Toft, Founder and CEO of The Toft Group Executive Search and Sabrina Johnson, President and CEO, Daré Bioscience join Pharm Exec editors to talk about the future of the life sciences executive.

Pharm Exec editors speak with Jigar Raythatha, CEO of Constellation Pharmaceuticals. He talks about his roles, the importance of having a Plan B in biotech, creating a translationally enabled company, and how he leads his team at Constellation.

Pharm Exec's European Editor, Julian Upton, speaks with Johnson & Johnson's Jennifer Turgiss, VP Behavior Science & Advanced Analytics group. In their interview, Turgiss discusses behavioral strategies to the health and wellness solutions being developed at J&J.

Editor-in-Chief Lisa Henderson speaks with Bill Newell, CEO of Sutro Biopharma about his background in corporate law and how it helps him in his role as a biotech executive, the importance of collaboration between big pharma and biotech, a story about keeping the San Francisco Giants in the Bay area, and other analogies around sports related to running a biotech.

Commercialization is a tough road to navigate even for the most established bio/pharmaceutical therapies. But as cell and gene therapies (CGTs) continue to form roots and make a splash worldwide—but specifically in the US—commercialization forms its own version of standardization and best practices.
In this exclusive interview with Pharmaceutical Executive, Lung-I Cheng, vice president of CGT, Cencora (formerly AmerisourceBergen), discusses:
1) defining CGT commercialization strategies and foundational knowledge—and the best music metaphor
2) what he wishes companies knew about commercialization strategies
3) common knowledge gaps of CGTs
4) how CGT developers can overcome key challenges, including those related to patient access, regulatory requirements, and market access
5) how planning for allogeneic cell therapies differs from autologous cell therapies and gene therapies
6) how companies can demonstrate CGT value as more products enter the development pipeline (and competition intensifies)
7) when to start planning a CGT commercialization strategy
8) predictions for the CGT market in five years

Pharm Exec editors interview Anna Sundgren, the renal disease strategy leader, Global Medicines Development at AstraZeneca, about the current CVRM landscape, challenges to renal drug development, and new therapeutics for chronic kidney disease.
This podcast was brought to you by QxMD.

Pharm Exec's European Editor, Julian Upton, caught up with Ben Wiegand, head of J&J's World Without Disease Accelerator unit, at eyeforpharma Barcelona. They talk about Wiegand's panel "Uniting Patients, Providers, and Payers to Bring Preventative Care to Life," and J&J's disease prevention and interception activities.
This podcast was brought to you by QxMD.

Michelle Maskaly and Christen Harm speak with Bill Carson, President & CEO of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Kabir Nath, President & CEO of Otsuka North America Pharmaceuticals about digital medicine, mental health therapies, and creating a smooth and collaborative relationship between R&D and commercial.